Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

被引：0
|
作者：
Andreas Teufel
Silke Steinmann
Jürgen Siebler
Christiane Zanke
Herbert Hohl
Bernd Adami
M Schroeder
O Klein
Thomas Höhler
Peter R Galle
Michael Heike
Markus Moehler
机构：
[1] Johannes Gutenberg University,Dept. of Internal Medicine I, Outpatient Unit for GI Cancer
[2] Hospital Bad Ems,undefined
[3] Outpatient Unit,undefined
[4] General practice,undefined
[5] General practice,undefined
[6] General practice,undefined
来源：
BMC Cancer | / 4卷
关键词：
irinotecan; 5-fluorouracil; safety; metastatic colorectal cancer; neoadjuvant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] FIRST LINE CHEMOTHERAPY (FLC) USING IRINOTECAN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFIRI) COMBINED WITH BEVACIZUMAB IN MEATASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 62 - 62
  • [42] Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial.
    Schalhorn, A
    Ludwig, FW
    Quietzsch, D
    Maubach, PA
    Schlimok, G
    Lambertz, H
    Weigang-Koehler, K
    Schulze, M
    Schlag, R
    Grundeis, M
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [43] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [44] Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: Is this really a dangerous treatment?
    Idelevich, E
    Man, S
    Lavrenkov, K
    Gluzman, A
    Geffen, DB
    Shani, A
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (05) : 487 - 490
  • [45] Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer
    Yalcin, S
    Oksuzoglu, B
    Tekuzman, G
    Engin, H
    Celik, I
    Turker, A
    Barista, I
    Gullu, I
    Guler, N
    Altundag, K
    Ozisik, Y
    Kars, A
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (11) : 580 - 583
  • [46] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
  • [47] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [48] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Cassidy, Jim
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2006 - 2012
  • [49] Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
    Aranda, E.
    Valladares, M.
    Martinez-Villacampa, M.
    Benavides, M.
    Gomez, A.
    Massutti, B.
    Marcuello, E.
    Constenla, M.
    Camara, J. C.
    Carrato, A.
    Duenas, R.
    Reboredo, M.
    Navarro, M.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2009, 20 (02) : 251 - 257
  • [50] Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    Folprecht, G
    Lutz, MP
    Schöffski, P
    Seufferlein, T
    Nolting, A
    Pollert, P
    Köhne, CH
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 450 - 456
12345